#Obesity medicine

Chronic weight management as a clinical specialty.

REDEFINE 3 has published its CagriSema trial design and baseline cohort, but cardiovascular outcome results remain pending.

A 24-week Indian phase 3 trial found Sun Pharma's synthetic semaglutide non-inferior to Wegovy for percentage weight change.

A 2026 meta-analysis found no significant MACE difference versus GLP-1 drugs, with high heterogeneity and mostly observational evidence.

A matched UK cohort linked tirzepatide use to lower weight, HbA1c and insulin needs in type 1 diabetes, but it was not randomized.

A 2026 practical guide organizes obesity prescribing decisions, but it is not a new trial and does not establish a semaglutide-tirzepatide winner.

Two 2026 letters discuss missed oral semaglutide doses, but inaccessible text limits what can be verified beyond the current product label.

A pooled STEP analysis found more gallbladder events with semaglutide 2.4 mg than placebo, but the absolute event rate remained low.

An engineered GLP-1/GIP molecule led its mouse-study comparisons, but the preclinical result cannot predict human weight loss or safety.

A post hoc SURMOUNT-1 analysis found limited regain was common during continued tirzepatide treatment, but selection limits matter.

A 2026 review links obesity treatment with better sleep-apnea measures. We separate its conclusions from the randomized tirzepatide evidence.

A matched US database study links GLP-1 drug use in sleep apnea with fewer strokes, hospital visits and deaths, but it cannot prove cause and effect.

A 2026 systematic review links pediatric GLP-1 medicines with lower BMI or HbA1c, while highlighting gastrointestinal effects and long-term gaps.